BioPharma Dive - Latest News

Bluebird says Ayrmid missed deadline for rival takeover bid

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about $29 million upfront.

Apr 16, 2025 - 22:33
 0
Bluebird says Ayrmid missed deadline for rival takeover bid

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about $29 million upfront.

Read More

Tags:

Previous Article

The Science Behind Why Roads Look Wet On Hot Days

Next Article

Legal Nonprofit Backs Away From Diversity. That Should Scare Everyone.

Related Posts

Mallinckrodt, Endo to combine in $7B deal

Mallinckrodt, Endo to combine in $7B deal

Mar 13, 2025  0

First Prader-Willi drug to reduce hunger approved by FDA

First Prader-Willi drug to reduce hunger approved by FDA

Mar 26, 2025  0

Trump signals plan to address ‘pill penalty’ of drug pricing law

Trump signals plan to address ‘pill penalty’ of drug pr...

Apr 16, 2025  0